About: Setipiprant

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan.

Property	Value
dbo:abstract	Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. (en)
dbo:casNumber	866460-33-5
dbo:fdaUniiCode	BHF20LA2GM
dbo:kegg	D10326
dbo:pubchem	49843471
dbo:thumbnail	wiki-commons:Special:FilePath/Setipiprant.svg?width=300
dbo:wikiPageExternalLink	http://adisinsight.springer.com/drugs/800018368
dbo:wikiPageID	47626347 (xsd:integer)
dbo:wikiPageLength	13190 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1120769337 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Eosinophilia dbc:Receptor_antagonists dbr:Area_under_the_curve_(pharmacokinetics) dbr:Pharmaceutical_drug dbr:In_vitro dbr:Interleukin_13 dbr:Interleukin_4 dbr:Interleukin_5 dbr:Alopecia dbr:Prostaglandin_D2_receptor dbr:Prostaglandin_D2_synthase dbr:Prostaglandin_DP2_receptor dbc:1-Naphthyl_compounds dbc:Prostaglandins dbr:Lymphocytes dbr:Clinical_trial dbr:Receptor_antagonist dbr:G-protein-coupled_receptor dbr:Dissociation_constant dbr:DMSO dbr:Actelion dbr:Allergan dbr:Allergens dbr:Cytokines dbr:Basophils dbr:Eosinophils dbr:Half-life dbr:International_Nonproprietary_Name dbr:Androgenic_alopecia dbr:Asthma dbr:Bioavailability dbr:Cmax_(pharmacology) dbr:White_blood_cells dbr:CYP3A4 dbr:Placebo dbr:Fevipiprant dbr:Ramatroban dbr:Male_pattern_baldness dbr:PTGS1 dbr:Thromboxane_receptor dbr:Investigational_drug dbr:Th2-cells
dbp:atcPrefix	none (en)
dbp:c	24 (xsd:integer)
dbp:casNumber	866460 (xsd:integer)
dbp:chemspiderid	29738718 (xsd:integer)
dbp:f	1 (xsd:integer)
dbp:h	19 (xsd:integer)
dbp:iupacName	2 (xsd:integer)
dbp:kegg	D10326 (en)
dbp:legalStatus	Investigational (en)
dbp:n	2 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	49843471 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	c15ccccc5cccc1CNCc2c3ncc2cc4F (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	IHAXLPDVOWLUOS-UHFFFAOYSA-N (en)
dbp:unii	BHF20LA2GM (en)
dbp:wikiPageUsesTemplate	dbt:Other_dermatological_preparations dbt:As_of dbt:Drugbox dbt:Reflist dbt:Prostanoid_signaling_modulators
dcterms:subject	dbc:Receptor_antagonists dbc:1-Naphthyl_compounds dbc:Prostaglandins
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. (en)
rdfs:label	Setipiprant (en)
owl:sameAs	yago-res:Setipiprant wikidata:Setipiprant https://global.dbpedia.org/id/zgfM
prov:wasDerivedFrom	wikipedia-en:Setipiprant?oldid=1120769337&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Setipiprant.svg
foaf:isPrimaryTopicOf	wikipedia-en:Setipiprant
is dbo:wikiPageWikiLink of	dbr:Prostaglandin_DP2_receptor dbr:Fevipiprant dbr:List_of_drugs:_Se–Sh
is foaf:primaryTopic of	wikipedia-en:Setipiprant